NCT06209671View on ClinicalTrials.gov

INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

January 15, 2025

Study Completion Date

January 15, 2026

Conditions
Leukemia, B-cell
Interventions
BIOLOGICAL

INS19 CAR-T Cells

INS19 CAR-T Cells, 1-2×10\^7 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline.

All Listed Sponsors
collaborator

Peking University People's Hospital

OTHER

lead

Beijing Immunochina Medical Science & Technology Co., Ltd.

INDUSTRY

NCT06209671 - INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter